Review



real world ulcerative colitis uc disease specific programme  (Adelphi Technology Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Adelphi Technology Inc real world ulcerative colitis uc disease specific programme
    A schematic diagram of the seven groups of patients with <t>ulcerative</t> colitis included in this study. Patients with disease extending beyond the rectum at diagnosis but regressed to IP at consultation were excluded from this study ( n = 105). *Other consists of patients with a disease extension of; left-sided ulcerative colitis or extensive colitis. IP, isolated proctitis; MEUC, more extensive ulcerative colitis; MUEC IM/AT, more extensive ulcerative colitis immunomodulator/advanced therapy; PPE, proctitis with proximal extension.
    Real World Ulcerative Colitis Uc Disease Specific Programme, supplied by Adelphi Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/real+world+ulcerative+colitis+uc+disease+specific+programme/pmc13167275-181-36-35?v=Adelphi+Technology+Inc
    Average 86 stars, based on 1 article reviews
    real world ulcerative colitis uc disease specific programme - by Bioz Stars, 2026-08
    86/100 stars

    Images

    1) Product Images from "Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States"

    Article Title: Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States

    Journal: Therapeutic Advances in Gastroenterology

    doi: 10.1177/17562848261448080

    A schematic diagram of the seven groups of patients with ulcerative colitis included in this study. Patients with disease extending beyond the rectum at diagnosis but regressed to IP at consultation were excluded from this study ( n = 105). *Other consists of patients with a disease extension of; left-sided ulcerative colitis or extensive colitis. IP, isolated proctitis; MEUC, more extensive ulcerative colitis; MUEC IM/AT, more extensive ulcerative colitis immunomodulator/advanced therapy; PPE, proctitis with proximal extension.
    Figure Legend Snippet: A schematic diagram of the seven groups of patients with ulcerative colitis included in this study. Patients with disease extending beyond the rectum at diagnosis but regressed to IP at consultation were excluded from this study ( n = 105). *Other consists of patients with a disease extension of; left-sided ulcerative colitis or extensive colitis. IP, isolated proctitis; MEUC, more extensive ulcerative colitis; MUEC IM/AT, more extensive ulcerative colitis immunomodulator/advanced therapy; PPE, proctitis with proximal extension.

    Techniques Used: Biomarker Discovery, Isolation

    Most common physician-reported symptoms across patients with varying disease extent. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy—advanced therapy includes biologics and Janus kinase inhibitor; IP, isolated proctitis; MEUC, more extensive ulcerative colitis.
    Figure Legend Snippet: Most common physician-reported symptoms across patients with varying disease extent. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy—advanced therapy includes biologics and Janus kinase inhibitor; IP, isolated proctitis; MEUC, more extensive ulcerative colitis.

    Techniques Used: Biomarker Discovery, Isolation

    Physician-reported derived total Mayo scores at the time of consultation across patients with varying disease extension. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy; IP, isolated proctitis; MEUC, more extensive ulcerative colitis; UC ulcerative colitis.
    Figure Legend Snippet: Physician-reported derived total Mayo scores at the time of consultation across patients with varying disease extension. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy; IP, isolated proctitis; MEUC, more extensive ulcerative colitis; UC ulcerative colitis.

    Techniques Used: Derivative Assay, Biomarker Discovery, Isolation

    Physician-reported type of therapy received since diagnosis and at consultation across patients with varying disease extension. Patient groups: all patients with IP ( n = 221), non-refractory IP ( n = 118), refractory IP ( n = 103), MEUC ( n = 1607), and MEUC IM/AT ( n = 1308). AT includes biologic agents (anti-tumor necrosis factor, -integrin, and -interleukin) and JAK inhibitors. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. 5-ASA, 5-aminosalicylic acid; AT, advanced therapy; CI, confidence interval; IM, immunomodulator; IP, isolated proctitis; JAK, Janus kinase; MEUC, more extensive ulcerative colitis.
    Figure Legend Snippet: Physician-reported type of therapy received since diagnosis and at consultation across patients with varying disease extension. Patient groups: all patients with IP ( n = 221), non-refractory IP ( n = 118), refractory IP ( n = 103), MEUC ( n = 1607), and MEUC IM/AT ( n = 1308). AT includes biologic agents (anti-tumor necrosis factor, -integrin, and -interleukin) and JAK inhibitors. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. 5-ASA, 5-aminosalicylic acid; AT, advanced therapy; CI, confidence interval; IM, immunomodulator; IP, isolated proctitis; JAK, Janus kinase; MEUC, more extensive ulcerative colitis.

    Techniques Used: Biomarker Discovery, Isolation

    Number of AT lines received at the time of consultation across patients with varying disease extension. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy; IP, isolated proctitis; MEUC, more extensive ulcerative colitis; UC, ulcerative colitis.
    Figure Legend Snippet: Number of AT lines received at the time of consultation across patients with varying disease extension. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy; IP, isolated proctitis; MEUC, more extensive ulcerative colitis; UC, ulcerative colitis.

    Techniques Used: Biomarker Discovery, Isolation



    Similar Products

    real world ulcerative colitis uc disease specific programme  (Adelphi Technology Inc)
    86
    Adelphi Technology Inc real world ulcerative colitis uc disease specific programme
    A schematic diagram of the seven groups of patients with <t>ulcerative</t> colitis included in this study. Patients with disease extending beyond the rectum at diagnosis but regressed to IP at consultation were excluded from this study ( n = 105). *Other consists of patients with a disease extension of; left-sided ulcerative colitis or extensive colitis. IP, isolated proctitis; MEUC, more extensive ulcerative colitis; MUEC IM/AT, more extensive ulcerative colitis immunomodulator/advanced therapy; PPE, proctitis with proximal extension.
    Real World Ulcerative Colitis Uc Disease Specific Programme, supplied by Adelphi Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/real+world+ulcerative+colitis+uc+disease+specific+programme/pmc13167275-181-36-35?v=Adelphi+Technology+Inc
    Average 86 stars, based on 1 article reviews
    real world ulcerative colitis uc disease specific programme - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    A schematic diagram of the seven groups of patients with ulcerative colitis included in this study. Patients with disease extending beyond the rectum at diagnosis but regressed to IP at consultation were excluded from this study ( n = 105). *Other consists of patients with a disease extension of; left-sided ulcerative colitis or extensive colitis. IP, isolated proctitis; MEUC, more extensive ulcerative colitis; MUEC IM/AT, more extensive ulcerative colitis immunomodulator/advanced therapy; PPE, proctitis with proximal extension.

    Journal: Therapeutic Advances in Gastroenterology

    Article Title: Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States

    doi: 10.1177/17562848261448080

    Figure Lengend Snippet: A schematic diagram of the seven groups of patients with ulcerative colitis included in this study. Patients with disease extending beyond the rectum at diagnosis but regressed to IP at consultation were excluded from this study ( n = 105). *Other consists of patients with a disease extension of; left-sided ulcerative colitis or extensive colitis. IP, isolated proctitis; MEUC, more extensive ulcerative colitis; MUEC IM/AT, more extensive ulcerative colitis immunomodulator/advanced therapy; PPE, proctitis with proximal extension.

    Article Snippet: Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Real World Ulcerative Colitis (UC) Disease Specific Programme (DSP)TM.

    Techniques: Biomarker Discovery, Isolation

    Most common physician-reported symptoms across patients with varying disease extent. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy—advanced therapy includes biologics and Janus kinase inhibitor; IP, isolated proctitis; MEUC, more extensive ulcerative colitis.

    Journal: Therapeutic Advances in Gastroenterology

    Article Title: Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States

    doi: 10.1177/17562848261448080

    Figure Lengend Snippet: Most common physician-reported symptoms across patients with varying disease extent. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy—advanced therapy includes biologics and Janus kinase inhibitor; IP, isolated proctitis; MEUC, more extensive ulcerative colitis.

    Article Snippet: Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Real World Ulcerative Colitis (UC) Disease Specific Programme (DSP)TM.

    Techniques: Biomarker Discovery, Isolation

    Physician-reported derived total Mayo scores at the time of consultation across patients with varying disease extension. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy; IP, isolated proctitis; MEUC, more extensive ulcerative colitis; UC ulcerative colitis.

    Journal: Therapeutic Advances in Gastroenterology

    Article Title: Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States

    doi: 10.1177/17562848261448080

    Figure Lengend Snippet: Physician-reported derived total Mayo scores at the time of consultation across patients with varying disease extension. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy; IP, isolated proctitis; MEUC, more extensive ulcerative colitis; UC ulcerative colitis.

    Article Snippet: Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Real World Ulcerative Colitis (UC) Disease Specific Programme (DSP)TM.

    Techniques: Derivative Assay, Biomarker Discovery, Isolation

    Physician-reported type of therapy received since diagnosis and at consultation across patients with varying disease extension. Patient groups: all patients with IP ( n = 221), non-refractory IP ( n = 118), refractory IP ( n = 103), MEUC ( n = 1607), and MEUC IM/AT ( n = 1308). AT includes biologic agents (anti-tumor necrosis factor, -integrin, and -interleukin) and JAK inhibitors. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. 5-ASA, 5-aminosalicylic acid; AT, advanced therapy; CI, confidence interval; IM, immunomodulator; IP, isolated proctitis; JAK, Janus kinase; MEUC, more extensive ulcerative colitis.

    Journal: Therapeutic Advances in Gastroenterology

    Article Title: Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States

    doi: 10.1177/17562848261448080

    Figure Lengend Snippet: Physician-reported type of therapy received since diagnosis and at consultation across patients with varying disease extension. Patient groups: all patients with IP ( n = 221), non-refractory IP ( n = 118), refractory IP ( n = 103), MEUC ( n = 1607), and MEUC IM/AT ( n = 1308). AT includes biologic agents (anti-tumor necrosis factor, -integrin, and -interleukin) and JAK inhibitors. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. 5-ASA, 5-aminosalicylic acid; AT, advanced therapy; CI, confidence interval; IM, immunomodulator; IP, isolated proctitis; JAK, Janus kinase; MEUC, more extensive ulcerative colitis.

    Article Snippet: Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Real World Ulcerative Colitis (UC) Disease Specific Programme (DSP)TM.

    Techniques: Biomarker Discovery, Isolation

    Number of AT lines received at the time of consultation across patients with varying disease extension. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy; IP, isolated proctitis; MEUC, more extensive ulcerative colitis; UC, ulcerative colitis.

    Journal: Therapeutic Advances in Gastroenterology

    Article Title: Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States

    doi: 10.1177/17562848261448080

    Figure Lengend Snippet: Number of AT lines received at the time of consultation across patients with varying disease extension. As part of the definition of the groups, patients in the non-refractory IP group had not received an IM or AT, and patients in the refractory IP and MEUC IM/AT groups had to have received IM or AT since diagnosis. CI, confidence interval; IM/AT, immunomodulator/advanced therapy; IP, isolated proctitis; MEUC, more extensive ulcerative colitis; UC, ulcerative colitis.

    Article Snippet: Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Real World Ulcerative Colitis (UC) Disease Specific Programme (DSP)TM.

    Techniques: Biomarker Discovery, Isolation